We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.475 | 1.45 | 1.50 | 1.475 | 1.475 | 1.475 | 34,085 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.28 | 11.4M |
From Apr 2019 to Apr 2024
TIDMSTX TIDMSTXW
RNS Number : 1931H
Shield Therapeutics PLC
15 August 2016
Shield Therapeutics plc
("Shield" or the "Company")
Notice of Interim Results
London, UK, 15 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces it will report its interim results for the six months ended 30 June 2016 on Tuesday 20 September 2016.
Carl Sterritt, Chief Executive Officer, Richard Jones, Chief Financial Officer, and Paul Steckler, VP Commercial Operations, will host a presentation and live conference call for analysts at 11.00am BST on the morning of results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)191 511 8507 Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer NOMAD Liberum Capital Limited Christopher Britton Steve Pearce +44 (0)20 3100 2222 Financial PR Advisor +44 (0)203 709 5700 Consilium Strategic Communications shieldtherapeutics@consilium-comms.com Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA). In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBBGDICBBBGLU
(END) Dow Jones Newswires
August 15, 2016 07:22 ET (11:22 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
